Menu Search
Equities

Gilead Sciences Inc

GISX:GER

Gilead Sciences Inc

Actions
  • Price (EUR)52.44
  • Today's Change0.91 / 1.77%
  • Shares traded10.15k
  • 1 Year change-8.13%
  • Beta0.4473
Data delayed at least 15 minutes, as of Jan 15 2021 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

  • Revenue in USD (TTM)23.15bn
  • Net income in USD1.27bn
  • Incorporated1987
  • Employees11.80k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttps://www.gilead.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GILD:NSQ since
announced		Transaction
value
MYR GmbHAnnounced10 Dec 202010 Dec 2020Announced4.13%1.75bn
Immunomedics IncDeal completed13 Sep 202013 Sep 2020Deal completed-3.43%20.77bn
Forty Seven IncDeal completed02 Mar 202002 Mar 2020Deal completed-8.69%4.88bn
Data delayed at least 15 minutes, as of Jan 15 2021 21:00 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.